Melinda G. Pauly

Hematology | Oncology
5461 Meridian Mark Rd Ste 400
Atlanta, GA 30342

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Ixazomib with chemotherapy for childhood relapsed acute lymphoblastic leukemia: a TACL consortium report.

Ixazomib with chemotherapy for childhood relapsed acute lymphoblastic leukemia: a TACL consortium report.

Journal: Blood neoplasia
Published: March 03, 2026

Carfilzomib plus induction chemotherapy in children with relapsed or refractory acute lymphoblastic leukemia.

Carfilzomib plus induction chemotherapy in children with relapsed or refractory acute lymphoblastic leukemia.

Journal: Blood advances
Published: January 22, 2026

Paired Tumor/Normal Sequencing Identifies a SEPT9::ABL1 Fusion in a Child With T-Cell Lymphoblastic Lymphoma.

Paired Tumor/Normal Sequencing Identifies a SEPT9::ABL1 Fusion in a Child With T-Cell Lymphoblastic Lymphoma.

Journal: Pediatric blood & cancer
Published: June 04, 2025

Vincristine Sulfate Liposome Injection With Combination Chemotherapy for Children, Adolescents, and Young Adults With Relapsed Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium Trial.

Vincristine Sulfate Liposome Injection With Combination Chemotherapy for Children, Adolescents, and Young Adults With Relapsed Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium Trial.

Journal: Pediatric blood & cancer
Published: December 09, 2024

Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia: Children's Oncology Group trial AALL15P1.

Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia: Children's Oncology Group trial AALL15P1.

Journal: Haematologica
Published: January 31, 2024

Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.

Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.

Journal: Cancers
Published: December 06, 2023

BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.

BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.

Journal: Journal for immunotherapy of cancer
Published: March 30, 2023

Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care.

Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care.

Journal: JCO precision oncology
Published: May 11, 2022

Phase 1b study of carfilzomib with induction chemotherapy in pediatric relapsed/refractory acute lymphoblastic leukemia.

Phase 1b study of carfilzomib with induction chemotherapy in pediatric relapsed/refractory acute lymphoblastic leukemia.

Journal: Pediatric blood & cancer
Published: May 03, 2022

Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation Rescues Marrow Failure From Acute Leukemia Therapy in a Patient With Previously Undiagnosed Ligase IV Syndrome.

Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation Rescues Marrow Failure From Acute Leukemia Therapy in a Patient With Previously Undiagnosed Ligase IV Syndrome.

Journal: Journal of pediatric hematology/oncology
Published: January 18, 2022

Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia.

Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia.

Journal: Nature communications
Published: August 20, 2021

Cryptic t(6;11) KMT2A rearrangement in a pediatric acute myeloid leukemia patient detected by next-generation sequencing and dual-fusion FISH analysis.

Cryptic t(6;11) KMT2A rearrangement in a pediatric acute myeloid leukemia patient detected by next-generation sequencing and dual-fusion FISH analysis.

Journal: Pediatric blood & cancer
Published: August 12, 2021
Showing 1-12 of 22

Last Updated: 09/26/2026